Clinical Trials Browser

Phase 2 × Head and Neck Neoplasms × pembrolizumab × Clear all

NCT03485209 2026-04-20

innovaTV 207

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04938609 2026-04-09

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05420948 2026-04-09

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Phase 2 Suspended

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05980000 2026-03-31

Rambro2

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04858269 2026-03-24

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07484139 2026-03-20

NEO COMBAT XL

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

7 enrolled 14 charts

GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT02296684 2026-01-15

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

67 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT02841748 2025-10-01

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04260126 2025-10-01

VERSATILE002

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05252429 2025-09-12

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

Head and Neck Neoplasms

NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04675294 2025-08-01

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05980598 2025-08-01

BelieveIT-201

Phase 2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04633278 2025-05-11

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Terminated

24 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Head and Neck Neoplasms

NCT06894459 2025-04-30

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Head and Neck Neoplasms

NCT02289209 2025-03-06

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Phase 2 Completed

48 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03085719 2025-02-25

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Phase 2 Active not recruiting

18 enrolled 22 charts

Head and Neck Neoplasms

NCT04857164 2025-01-28

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06793761 2025-01-27

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

Phase 2 Not yet recruiting

Head and Neck Neoplasms

NCT03813836 2024-11-12

POPPY

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02609503 2024-11-05

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

Phase 2 Completed

29 enrolled 27 charts

Head and Neck Neoplasms

NCT05265013 2024-11-04

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Phase 2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02641093 2024-08-29

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

96 enrolled 12 charts

Head and Neck Neoplasms

NCT05358548 2024-04-10

ATATcH Alternating Treatment Plans for Advanced Cancer

Phase 2 Recruiting

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT04936841 2024-04-04

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Phase 2 Terminated

5 enrolled 17 charts

Head and Neck Neoplasms

NCT03511391 2024-01-23

CHEERS

Phase 2 Completed

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT03532737 2024-01-23

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Phase 2 Unknown

Head and Neck Neoplasms

NCT03193931 2023-02-06

ELDORANDO

Phase 2 Terminated

Head and Neck Neoplasms

NCT05551767 2022-09-23

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Phase 2 Unknown

Head and Neck Neoplasms

NCT05025813 2022-08-01

DESQUAMATE

Phase 2 Recruiting

Head and Neck Neoplasms

NCT03695510 2022-04-21

ALPHA

Phase 2 Completed

Head and Neck Neoplasms

NCT04408898 2021-11-16

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT04058145 2020-09-07

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT03463161 2020-01-27

ORKA

Phase 2 Terminated

2 enrolled 5 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03325465 2019-04-22

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03238638 2018-01-04

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

Phase 2 Withdrawn

Head and Neck Neoplasms